FDA
-
-
-
-
-
-
-
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Entrada Therapeutics (TRDA)
-
-
-
-
-
-
-
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
After-hours movers: Lucid gains on liquidity boost, Entrada Therapeutics sinks on FDA hold
-
-
-
-
-
-
-
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
-
-
-
-
-
-
-
Entrada Therapeutics (TRDA) Reports New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle Therapeutics
-
-
323,582 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

